

Press Release

29 November 2021 09:00:00 CET

EU publishes an article about the successful finalization of 2cureX's MicroCaT project.

2cureX announced today that the European Commission has published an article about the EU funded MicroCaT project (H2020 no. 777718). EU selects a subset of the successful projects for publication at the Commissions website.

The MicroCaT project was successfully concluded on October 2021 ([2cureX successfully completed the EU-project MicroCaT and received the final financial tranche of a 3.0 MEUR grant. | 2cureX](#)). MicroCaT was a very ambitious project aimed at showing the clinical validity of 2cureX's IndiTreat test through a prospective interventional trial in metastatic colorectal cancer. The trial (TICC trial, NCT03251612) was an Investigator Initiated Trial where the clinical partners defined the clinical endpoint to be met. The project plan included the preparation of market entry after a successful clinical trial. Both objectives were met within the projected timeframe.

Fernando Andreu, CEO, 2cureX says “the MicroCaT project is a very good example of how EU-funding can boost creation of new technologies and make them available to European citizens and beyond. For 2cureX the funding came just at the right time. The IndiTreat technology had shown its usability in the laboratory; but was still missing the final clinical validation in patients. We are very grateful to our dedicated clinical partners and the 2cureX staff that made the successful completion possible. The MicroCaT project has allowed 2cureX to accelerate the development of the IndiTreat mCRC products and the roll-out into the European market. It is a pleasure to see that the EU shares our view on the importance of drug sensitivity testing for individualizing cancer patient treatments”.

Read the article [here](#)

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

Ole Thastrup, Chief Science Officer
E-mail: ot@2curex.com
Telephone: +45 2211 5399
www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first IndiTreat® test is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer facing their third line of therapy. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related *In Vitro Diagnostic* (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

Attachments

[EU publishes an article about the successful finalization of 2cureX's MicroCaT project.](#)